Photo for representation only. Source: iStock.
Zurich/Geneva, October 16
A World Health Organization (WHO) trial that concluded Gilead Sciences Inc. remdesivir did not significantly help COVID-19 patients is reliable, a scientist who evaluated it said on Friday, as the U.S. company criticized its methodology.
"It's a reliable result, don't let anybody tell you otherwise, because they'll try to," Richard Peto, an independent statistician hired by the WHO to evaluate its Solidarity trial, told reporters, adding that any benefit of remdesivir may be due to chance.
Gilead has questioned the findings that concluded remdesivir does not help patients who have been admitted to hospital, saying the "emerging (WHO) data appears inconsistent". Gilead was given data from the United Nations health agency's trial 10 days ago, to give it an opportunity to react. — Reuters
Join Whatsapp Channel of The Tribune for latest updates.
Most Read In 24 Hours
Don't Miss
View All
Top News
Israel says it is poised to move on Rafah to assault Hamas hold-outs
Netanyahu's Government said Israel 'moving ahead' with groun...
Tibetan government-in-exile, China holding back-channel talks; aiming to revive stalled dialogue process
From 2002 to 2010, Dalai Lama’s representatives and Chinese ...
JEE-Main 2024 result declared; 56 candidates score 100 percentile
Out of 56, 15 are from Telangana, 7 each from Andhra Pradesh...
DRG cop killed, another injured in accidental firing in Chhattisgarh’s Dantewada
The incident took place around 11 pm on Wednesday, say polic...
Phase-2 campaign ends, fate of Rahul Gandhi, Gajendra Shekhawat, HD Kumaraswamy, Hema Malini to be sealed
88 seats up for grabs across 13 states | Polling to conclude...
